ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-131536 | Pharmaceuticals
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Anxiety Disorders and Depression Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET
7.1 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ANXIETY DISORDERS AND DEPRESSION TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 1. Sumitomo Dainippon Pharma Co.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 2. Sage Therapeutics
16.3 3. GlaxoSmithKline plc
16.4 4. F. Hoffmann-La Roche Ltd
16.5 5. Eli Lilly and Company
16.6 6. Abbott
16.7 7. Sanofi
16.8 8. H. Lundbeck A/S
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Antidepressant Drugs, Atypical Antipsychotics, Benzodiazepines, Beta-Blockers ); Therapies ( Electroconvulsive Therapy (ECT), Psychotherapy, Deep Brain Stimulation, Cognitive Behavior Therapy (CBT), Cranial Electrotherapy Stimulation (CES), Trans Cranial Magnetic Stimulation (TMS)); Devices (Cranial Electrotherapy Stimulator, fisher-wallace stimulator); Application (Phobia, Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder, Major Depressive Disorder, other); End User (Hospitals, Mental Healthcare Centers, Other)Companies
1. Sumitomo Dainippon Pharma Co.
2. Sage Therapeutics
3. GlaxoSmithKline plc
4. F. Hoffmann-La Roche Ltd
5. Eli Lilly and Company
6. Abbott
7. Sanofi
8. H. Lundbeck A/S
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.